1. Каркищенко Н.Н. Альтернативы биомедицины. Т. 1. Основы биомедицины и фармакомоделирования. М.: Изд-во ВПК, 2007. 320 с.
2. Каркищенко Н.Н. Основы биомоделирования. М.: Межакадемическое изд-во ВПК, 2004. 607 с.
3. Руководство по лабораторным животным и альтернативным моделям в биомедицинских исследованиях / Под ред. Н.Н. Каркищенко и др. М.: Профиль-2С, 2010. 358 p.
4. Aoyagi T., Yamamoto N., Hatta M., Tanno D., Miyazato A., Ishii K., et al. Activation of pulmonary invariant NKT cells leads to exacerbation of acute lung injury caused by LPS through local production of IFN-γ and TNF-α by Gr-1+ monocytes. Int. Immunol. 2011;23(2):97–108.
5. Bacci M.R., Leme R.C., Zing N.P., Murad N., Adami F., Hinnig P.F., et al. IL-6 and TNF-α serum levels are associated with early death in community-acquired pneumonia patients. Braz. J. Med. Biol. Res. 2015;48(5):427–432.
6. Celli B.R., Locantore N., Yates J., Tal-Singer R., Miller B.E., Bakke P., et al. ECLIPSE Investigators. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2012;185(10):1065–1072.
7. Crosby C.M., Kronenberg M. Tissue-specific functions of invariant natural killer T cells. Nat. Rev. Immunol. 2018;18(9):559–574.
8. D’Alessio F.R. Mouse Models of Acute Lung Injury and ARDS. Methods Mol. Biol. 2018;1809:341–350.
9. Davey R.T. Jr., Lynfield R., Dwyer D.E., Losso M.H., Cozzi-Lepri A., Wentworth D., et al. INSIGHT FLU 002 & 003 Study Groups. The association between serum biomarkers and disease outcome in influenza A(H1N1)pdm09 virus infection: results of two international observational cohort studies. PLoS One. 2013;8(2):e57121.
10. Gubernatorova E.O., Gorshkova E.A., Polinova A.I., Drutskaya M.S. IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev. 2020;53:13–24.
11. Henry B.M., de Oliveira M.H.S., Benoit S., Plebani M., Lippi G. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin. Chem. Lab. Med. 2020;58(7):1021–1028.
12. Kudo D., Toyama M., Aoyagi T., Akahori Y., Yamamoto H., Ishii K., et al. Involvement of high mobility group box 1 and the therapeutic effect of recombinant thrombomodulin in a mouse model of severe acute respiratory distress syndrome. Clin. Exp. Immunol. 2013;173(2):276–287.
13. Liu T., Zhang L., Joo D., Sun S.C. NF-κB signaling in inflammation. Signal Transduct. Target. Ther. 2017;2. DOI: 10.1038/sigtrans.2017.23.
14. McGonagle D., Sharif K., O’Regan A., Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun. Rev. 2020;19(6):102537.
15. Ogawa C., Liu Y.J., Kobayashi K.S. Muramyl dipeptide and its derivatives: peptide adjuvant in immunological disorders and cancer therapy. Curr. Bioact. Compd. 2011;7(3):180–197.
16. Potey P.M., Rossi A.G., Lucas C.D., Dorward D.A. Neutrophils in the initiation and resolution of acute pulmonary inflammation: understanding biological function and therapeutic potential. J. Pathol. 2019;247(5):672–685.
17. Rincon M., Irvin C.G. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int. J. Biol. Sci. 2012;8(9):1281–1290.
18. Zhao J., Li X., Gao Y., Huang W. Risk factors for the exacerbation of patients with 2019 Novel Coronavirus: A meta-analysis. Int. J. Med. Sci. 2020;17(12):17441750.
